Antara AGEasy celebrates one year of advancing senior health solutions
AGEasy has made significant strides in addressing the pressing health concerns of seniors in India
AGEasy has made significant strides in addressing the pressing health concerns of seniors in India
The company recorded sales of Rs. 1,129 crore for the fiscal year ended June 30, 2024,
These digital initiatives are expected to enhance the accessibility and efficiency of drug safety monitoring and standards compliance
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
India Business grew by 11.9% YoY to Rs. 1196.2 crore
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
This project is supported by the Irish Government through IDA Ireland
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
Subscribe To Our Newsletter & Stay Updated